Nawras Habash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nawras Habash has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Imad Absah
Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW Rochester, Rochester, MN, 55905, USA
3 shared publications- Imad Absah
Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications Eva Morava
Department of Clinical Genomics Rochester MN
1 shared publicationJoseph A. Murray
Division of gastroenterology and hepatology Mayo Clinic Rochester MN
1 shared publicationRobert M. Jacobson
Division of Community Pediatric and Adolescent Medicine Division of Pediatric Infectious Diseases Rochester MN
1 shared publicationRok Seon Choung
Division of gastroenterology and hepatology Mayo Clinic Rochester MN
1 shared publication
Latest Publications
- 10 April 2026
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 101 (9) , 1602-1614
Hepatitis B Vaccine: Time to Rethink Our Correlate of Protection
- 10 April 2026
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 101 (9) , 1602-1614
Hepatitis B Vaccine: Time to Rethink Our Correlate of Protection
- 4 August 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (8) , 526
Functional immunity in hepatitis B: when titers don’t tell the whole story
- 4 August 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (8) , 526
Functional immunity in hepatitis B: when titers don’t tell the whole story
- Open Access
- 20 March 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-2
Hepatitis B Risk in Vaccinated Patients with Celiac Disease – Do Titers Matter?
- 20 March 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-2
Open AccessHepatitis B Risk in Vaccinated Patients with Celiac Disease – Do Titers Matter?
- 1 December 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 74 (3) , 328-332
Celiac Disease
Objective: The aim of our study was to assess the response to hepatitis B virus (HBV) vaccination and the risk of HBV infection in patients with celiac disease (CD).Patients and Methods: We performed a cross‐sectional study using the National Health and Nutrition Examination Survey (NHANES) database (2009–2014) to assess the rate of HBV vaccination, immune response, and HBV infection risk in patients with and without CD. We also determined the rate of HBV infection via retrospective analysis of two cohorts: patients seen at Mayo Clinic (1998–2021), and a stable longitudinally observed cohort, the Rochester Epidemiology Project (REP; 2010–2020).Results: Based on the NHANES data, the rate of HBV infection in the United States was 0.33% (95% confidence interval 0.25–0.41). Of 93 patients with CD, 46 (49%) were vaccinated for HBV and of the remaining 19,422 without CD, 10,228 (53%) were vaccinated. Twenty‐two (48%) vaccinated patients with CD had HBV immunity and 4405 (43.07%) vaccinated patients without CD had HBV immunity, which was not statistically different. In NHANES data, there were no cases of HBV infection in patients with CD. During the study period, 3568 patients with CD were seen at Mayo Clinic and 3918 patients with CD were identified using the REP database. Of those patients with CD, only four (0.11%) at Mayo Clinic and nine (0.23%) of the REP patients had HBV infection.Conclusion: The rate of HBV vaccination and immunity was similar in individuals with and without CD. Predictably, no increased risk of HBV infection was detected in CD patients. These results do not support screening and revaccination practice for HBV immunity in patients with CD within the United States.
- 1 December 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 74 (3) , 328-332
Celiac Disease
Objective: The aim of our study was to assess the response to hepatitis B virus (HBV) vaccination and the risk of HBV infection in patients with celiac disease (CD).Patients and Methods: We performed a cross‐sectional study using the National Health and Nutrition Examination Survey (NHANES) database (2009–2014) to assess the rate of HBV vaccination, immune response, and HBV infection risk in patients with and without CD. We also determined the rate of HBV infection via retrospective analysis of two cohorts: patients seen at Mayo Clinic (1998–2021), and a stable longitudinally observed cohort, the Rochester Epidemiology Project (REP; 2010–2020).Results: Based on the NHANES data, the rate of HBV infection in the United States was 0.33% (95% confidence interval 0.25–0.41). Of 93 patients with CD, 46 (49%) were vaccinated for HBV and of the remaining 19,422 without CD, 10,228 (53%) were vaccinated. Twenty‐two (48%) vaccinated patients with CD had HBV immunity and 4405 (43.07%) vaccinated patients without CD had HBV immunity, which was not statistically different. In NHANES data, there were no cases of HBV infection in patients with CD. During the study period, 3568 patients with CD were seen at Mayo Clinic and 3918 patients with CD were identified using the REP database. Of those patients with CD, only four (0.11%) at Mayo Clinic and nine (0.23%) of the REP patients had HBV infection.Conclusion: The rate of HBV vaccination and immunity was similar in individuals with and without CD. Predictably, no increased risk of HBV infection was detected in CD patients. These results do not support screening and revaccination practice for HBV immunity in patients with CD within the United States.
- Open Access
- 8 November 2021
- Published by Wiley in JPGN Reports
- Vol. 2 (4) , e137
An Adolescent with Chanarin‐Dorfman Syndrome Presenting with Ichthyosis and Hepatic Steatosis
Chanarin‐Dorfman syndrome also known as neutral lipid storage disease is a rare multisystemic autosomal recessive disorder. It is mostly encountered in patients of Mediterranean and Middle Eastern origin. Most patients are brought to medical attention secondary to dermatological manifestations namely ichthyosis. Here, we report a 10‐year‐old Kurdish male patient with ichthyosis, who was referred to pediatric liver clinic for transaminase elevation of unknown etiology despite elaborate workup. Histological findings on liver biopsy were consistent with nonalcoholic steatohepatitis. Genetic testing identified homozygous mutation C.776G>A (p.G259D) in the Abhydrolase domain containing 5 gene on chromosome 3 described in patients with Chanarin‐Dorfman syndrome. After the initiation of a diet with high medium chain triglycerides/long chain triglycerides ratio, aerobic exercise, and vitamin E, the patient liver enzymes improved. Due to debilitating ichthyosis, he was started on acitretin therapy that was discontinued due to transaminases elevation. Patient is currently stable and doing well.
- 8 November 2021
- Published by Wiley in JPGN Reports
- Vol. 2 (4) , e137
Open AccessAn Adolescent with Chanarin‐Dorfman Syndrome Presenting with Ichthyosis and Hepatic Steatosis
Chanarin‐Dorfman syndrome also known as neutral lipid storage disease is a rare multisystemic autosomal recessive disorder. It is mostly encountered in patients of Mediterranean and Middle Eastern origin. Most patients are brought to medical attention secondary to dermatological manifestations namely ichthyosis. Here, we report a 10‐year‐old Kurdish male patient with ichthyosis, who was referred to pediatric liver clinic for transaminase elevation of unknown etiology despite elaborate workup. Histological findings on liver biopsy were consistent with nonalcoholic steatohepatitis. Genetic testing identified homozygous mutation C.776G>A (p.G259D) in the Abhydrolase domain containing 5 gene on chromosome 3 described in patients with Chanarin‐Dorfman syndrome. After the initiation of a diet with high medium chain triglycerides/long chain triglycerides ratio, aerobic exercise, and vitamin E, the patient liver enzymes improved. Due to debilitating ichthyosis, he was started on acitretin therapy that was discontinued due to transaminases elevation. Patient is currently stable and doing well.
- Open Access
- 28 June 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 73 (4) , E105
Gastrointestinal Hemosiderosis
- 28 June 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 73 (4) , E105
Open AccessGastrointestinal Hemosiderosis